Investing.comCodex · 实盘不做把握 7/10
北京时间·🕒 发布 19:12:35时区推断·⟳ 抓取 19:24:57·⚡ 决策 08-04 22:45:19 +3h20m·84.3 天前
Dianthus公布自身免疫疾病早期管线DNTH312，预计2027年底才具备一期准备条件
DNTH312仍处于临床前阶段，距离2027年底Phase 1 ready仍有一年以上，短期没有收入、临床读出或监管里程碑增量。
📄 原文Investing.com↗ 原文
Dianthus announces DNTH312 bifunctional protein for autoimmune diseases
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets NEW YORK and WALTHAM, Mass. - Dianthus Therape…
不做 Dianthus Therapeutics（DNTH.US）
临床前候选分子披露，Phase 1 ready目标在2027年底且无授权、收入或近期临床读出，短线无足够edge，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 low · price-in 风险 medium ↗
关键理由
- DNTH312仍处于临床前阶段，距离2027年底Phase 1 ready仍有一年以上，短期没有收入、临床读出或监管里程碑增量。
- 公告主要是公司自身管线扩展和体外/非人灵长类数据披露，尚不足以形成可回测的短线基本面重定价。
主要风险
- 若后续出现授权合作、加速进入临床或关键疾病适应症数据，需作为新催化重新评估。
原文全文
展开原文 · 1,867 字
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets
NEW YORK and WALTHAM, Mass. - Dianthus Therapeutics, Inc. (NASDAQ:DNTH) announced today a new pipeline candidate, DNTH312, an investigational bifunctional fusion protein combining claseprubart and TACI technologies, according to a company press release.
DNTH312 targets inhibition of active C1s and BAFF/APRIL pathways. The company stated the molecule demonstrated comparable in vitro potency and aC1s inhibition to claseprubart across several functional assays of Classical Pathway inhibition.
In non-human primate studies, DNTH312 showed a half-life of 22 days, similar to claseprubart, which has an approximately 60-day half-life in humans. The molecule also demonstrated similar depth of IgM, IgA, and IgG reduction following a single dose in non-human primates compared to povetacicept.
"DNTH312 combines upstream and downstream inhibition of pathways often responsible for the morbidity seen in autoantibody mediated diseases such as MG, CIDP and MMN," said Simrat Randhawa, Executive Vice President and Head of Research and Development at Dianthus Therapeutics.
The molecule incorporates YTE half-life extension technology and is designed for subcutaneous self-administration. Dianthus stated the company expects intellectual property protection for DNTH312 through at least 2047, compared to claseprubart IP protection expected through at least 2043.
The company aims to have DNTH312 Phase 1 ready by the end of 2027. DNTH312 is not approved as a therapy in any indication in any jurisdiction worldwide.
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, based in New York City and Waltham, Massachusetts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK and WALTHAM, Mass. - Dianthus Therapeutics, Inc. (NASDAQ:DNTH) announced today a new pipeline candidate, DNTH312, an investigational bifunctional fusion protein combining claseprubart and TACI technologies, according to a company press release.
DNTH312 targets inhibition of active C1s and BAFF/APRIL pathways. The company stated the molecule demonstrated comparable in vitro potency and aC1s inhibition to claseprubart across several functional assays of Classical Pathway inhibition.
In non-human primate studies, DNTH312 showed a half-life of 22 days, similar to claseprubart, which has an approximately 60-day half-life in humans. The molecule also demonstrated similar depth of IgM, IgA, and IgG reduction following a single dose in non-human primates compared to povetacicept.
"DNTH312 combines upstream and downstream inhibition of pathways often responsible for the morbidity seen in autoantibody mediated diseases such as MG, CIDP and MMN," said Simrat Randhawa, Executive Vice President and Head of Research and Development at Dianthus Therapeutics.
The molecule incorporates YTE half-life extension technology and is designed for subcutaneous self-administration. Dianthus stated the company expects intellectual property protection for DNTH312 through at least 2047, compared to claseprubart IP protection expected through at least 2043.
The company aims to have DNTH312 Phase 1 ready by the end of 2027. DNTH312 is not approved as a therapy in any indication in any jurisdiction worldwide.
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, based in New York City and Waltham, Massachusetts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。